In this regard and based on our observations, we are currently evaluating if a correlation exists between FJX1 peptide-specific immune response and the expression of FJX1 in patients’ tumors, as well as the presence of immunosuppression or immune checkpoint in NPC patients. Here, FJX1 is linked to nasopharyngeal carcinoma.